Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a novel polypeptide for improving placental dysfunction in preeclampsia

A technology for dysfunction and preeclampsia, applied in the field of medicine, can solve problems such as maternal and fetal side effects, and achieve the effects of good stability, improvement of proteinuria symptoms, and good lipophilicity

Active Publication Date: 2022-07-22
NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide an application of a novel polypeptide for improving placental dysfunction in preeclampsia, so as to solve the problem that most of the drugs for improving placental dysfunction in preeclampsia have certain toxic and side effects on mother and fetus.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a novel polypeptide for improving placental dysfunction in preeclampsia
  • Application of a novel polypeptide for improving placental dysfunction in preeclampsia
  • Application of a novel polypeptide for improving placental dysfunction in preeclampsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Further, the application of the polypeptide in the medicine or medicament for improving placental dysfunction in preeclampsia, wherein the polypeptide and the polypeptide composition can be made into any pharmaceutically acceptable dosage form.

[0026] Rats were housed in a light- and humidity-controlled environment, with free access to food and tap water, and were acclimated to these conditions for a week. Fertile females and males were reared at a 1:1 ratio overnight, and plugs were collected in the morning, as in Presence confirms pregnancy and this day is GD0. At 14 days of gestation, pregnant mice were randomly assigned to three groups. Group 1 (Saline) (n=10): On day 14 of gestation, each rat received normal saline (1 mg / kg) via tail vein; Group 2 (LPS): On day 14 of gestation, LPS was injected via tail vein (1 μg / kg); Group 3 (LPS+Cys-peptide): On the 14th day of gestation, the rats were first treated with LPS (1 μg / kg) via the tail vein, and then administered ...

Embodiment 2

[0033] Further, the application of polypeptide in reducing the level of urine protein / creatinine in pregnant mice with preeclampsia.

[0034] Sprague-Dawley (SD) rats (10-12 weeks, 280-350 g) were purchased from the Experimental Animal Center of Nanjing Medical University. Rats were housed in a light- and humidity-controlled environment with ad libitum food and tap water ad libitum.

[0035] After one week of acclimatization, fertile females and males were reared at a ratio of 1:1 overnight, and plugs were picked up in the morning. If they were present, pregnancy was confirmed, and this day was GD0. (Under standard laboratory conditions (temperature 23-26°C, relative humidity 50-60%, irradiation between 06:00am and 06:00pm), free access to pelleted food and water)

[0036] On day 14 of gestation, pregnant rats were randomly assigned to three groups: group 1 (Saline) (n=10): on day 14 of gestation, each rat received saline (1 mg / kg) via the tail vein; group 2 (PE) Rats were i...

Embodiment 3

[0041] Further, the application of polypeptide in improving the utilization rate of placenta in pregnant mice with preeclampsia.

[0042] Prague-Dawley (SD) rats (10-12 weeks, 280-350 g) were purchased from the Experimental Animal Center of Nanjing Medical University. Rats were housed in a light- and humidity-controlled environment with ad libitum food and tap water ad libitum.

[0043] After one week of acclimatization, fertile females and males were reared at a ratio of 1:1 overnight, and plugs were picked up in the morning. If they were present, pregnancy was confirmed, and this day was GD0. (Under standard laboratory conditions (temperature 23-26°C, relative humidity 50-60%, irradiation between 06:00am and 06:00pm), free access to pelleted food and water)

[0044] On day 14 of gestation, pregnant rats were randomly assigned to three groups: group 1 (Saline) (n=10): on day 14 of gestation, each rat received saline (1 mg / kg) via the tail vein; group 2 (PE) Rats were inject...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a novel polypeptide for improving placental dysfunction in preeclampsia, relates to the related field of medicine, and solves the problem that most drugs in the prior art for improving placental dysfunction in preeclampsia have certain toxic and side effects on the mother and fetus. The application of the polypeptide is in the preparation of a medicine or a medicament for improving placental dysfunction in preeclampsia; the polypeptide sequence is Ac-RFAACAA-COOH.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of a novel polypeptide for improving placental dysfunction in preeclampsia. Background technique [0002] Pre-eclampsia (PE) is a disease unique to pregnancy, which can cause multiple organ dysfunction, cerebral edema, and fetal growth restriction in pregnant women. It is one of the diseases with the highest mortality rate of pregnant women and fetuses. According to statistics, about 49,000 pregnant women and 50,000 perinatal infants die of preeclampsia and its complications every year, accounting for 14% of all maternal deaths; the incidence of PE in my country is as high as 3.91-5.57%, which seriously endangers women and fetal health. At present, except for a few drugs such as labetalol and nifedipine, which are relatively safe, the rest all have toxic and side effects on the mother and fetus; today, when the treatment measures are extremely lacking, termination of pregn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K38/08A61P15/00
CPCC07K7/06A61P15/00A61K38/00
Inventor 丁虹娟贾瑞喆崔县伟沈嵘凌钟慧季小红薛路
Owner NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com